Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Regeneron Pharmaceuticals Inc    REGN

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
02/16/2017 02/17/2017 02/21/2017 02/22/2017 02/23/2017 Date
373.02(c) 371.18(c) 371.61(c) 370.22(c) 360.96(c) Last
1 277 299 775 547 722 557 569 426 1 119 121 Volume
-2.86% -0.49% +0.12% -0.37% -2.50% Change
More quotes
Financials ($)
Sales 2017 5 499 M
EBIT 2017 2 174 M
Net income 2017 1 050 M
Finance 2017 2 763 M
Yield 2017 -
Sales 2018 6 202 M
EBIT 2018 2 740 M
Net income 2018 1 349 M
Finance 2018 4 949 M
Yield 2018 -
P/E ratio 2017 41,02
P/E ratio 2018 31,51
EV / Sales2017 6,46x
EV / Sales2018 5,38x
Capitalization 38 291 M
More Financials
Company
Regeneron Pharmaceuticals, Inc. operates as a biopharmaceutical company.It discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.The company involves in marketing medicines for eye diseases, colorectal cancer and a rare inflammatory... 
Sector
Biotechnology & Medical Research
Calendar
03/06 | 07:05pmPresentation
More about the company
Surperformance© ratings of Regeneron Pharmaceuticals
Trading Rating : Investor Rating :
More Ratings
Latest news on REGENERON PHARMACEUTICALS
02/16 REGENERON PHARMACEUTICALS : Appeals Court Grants Stay of Permanent Injunction fo..
02/16 REGENERON PHARMACEUTICALS : Findings from Regeneron Pharmaceuticals in the Area ..
02/13 REGENERON PHARMACEUTICALS : Announces Upcoming 2017 Investor Conference Presenta..
02/09 REGENERON PHARMACEUTICALS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CO..
02/09 REGENERON PHARMACEUTICALS : and Sanofi Announce First Approval of Kevzara sarilu..
02/09 REGENERON PHARMACEUTICALS : Appeals Court Grants Stay of Permanent Injunction fo..
02/09 REGENERON PHARMACEUTICALS, INC. (NAS : REGN) Files An 8-K Results of Operations ..
02/09 REGENERON PHARMACEUTICALS INC : Results of Operations and Financial Condition, F..
02/09 REGENERON PHARMACEUTICALS : misses Street 4Q forecasts
02/09 REGENERON PHARMACEUTICALS INC (NASDA : REGN) And Sanofi SA (ADR)(NYSE:SNY) Loses..
More news
Sector news : Bio Therapeutic Drugs
02/22 Genmab and J&J's cancer drug set for blockbuster sales this year
02/21 Icahn buys Bristol-Myers shares, adding to activist pressure
02/21DJBristol-Myers Expands Board, Boosts Buybacks Amid Activist Pressure
02/16 How Sanofi lost out to J&J in $30 billion battle for Actelion
02/14 Gilead challenges GSK with strong HIV drug data
More sector news : Bio Therapeutic Drugs
Latest Tweets
02/23Investors Should Not Focus Too Much On Dividends
1
02/23Merrill Lynch sees top large cap Biotech Stocks being the cheapest they have .. 
02/23$REGN - Highlights from RBC Healthcare Conference Atopic Dermatitis Panel 
02/22Valeant: Price Target Over $30  
02/17What Makes Amgen A Compelling Buy In 2017?  
More tweets
Qtime:73
News from SeekingAlpha
02/23 Investors Should Not Focus Too Much On Dividends
02/22 VALEANT : Price Target Over $30
02/17 What Makes Amgen A Compelling Buy In 2017?
02/13 Premarket analyst action - healthcare
02/10 Praluent Stay Not Enough To Save Regeneron
Advertisement
Chart REGENERON PHARMACEUTICALS
Duration : Period :
Regeneron Pharmaceuticals  Technical Analysis Chart | REGN | US75886F1075 | 4-Traders
Full-screen chart
Technical analysis trends REGENERON PHARMAC...
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 423 $
Spread / Average Target 17%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
George Damis Yancopoulos President & Chief Scientific Officer
P. Roy Vagelos Chairman
Robert E. Landry Chief Financial Officer & Senior VP-Finance
Charles A. Baker Independent Class III Director
Michael S. Brown Independent Class I Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
REGENERON PHARMACEUTIC..0.85%38 291
AMGEN, INC.18.06%128 150
CELGENE CORPORATION3.04%92 936
GILEAD SCIENCES, INC.-3.13%91 392
ACTELION LTD22.45%28 790
VERTEX PHARMACEUTICALS..16.45%21 264
More Results